|
|
Please use the following Index to navigate to the different sections:
|
 |
|
Index:
|
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
|
|
•
|
|
|
|
Post-graduate programmes:
|
|
All post graduate programmes are managed by the focus area. We offer Masters, Ph.D as well as Post Doctoral training. Students can do an academic internship during their Masters degree studies in the School of Pharmacy.
MAGISTER SCIENTIAE:
In the School of Pharmacy a M.Sc. can be obtained in Pharmacology, Pharmaceutical Chemistry and Pharmaceutics.
|
|
•
|
Admission requirements:
Students in possession of a four year B.Sc.(Farm), or B.Pharm. degree, or a Hons.B.Sc. in a relevant field of study or a qualification deemed equivalent by the Senate, will be admitted. In the case of a three year B.Sc.(Farm) or B.Pharm. degree, additional courses as determined by the Subject Leader will be required.
|
|
•
|
Minimum duration:
The minimum duration of the study is two years.
|
|
•
|
|
Courses:
|
|
Module |
Description |
|
FKLG891
|
Pharmacology
|
|
FCHG891
|
Pharmaceutical Chemistry
|
|
FMSG891
|
Pharmaceutics
|
|
|
•
|
Curriculum:
|
|
|
-
|
A dissertation on a approved subject.
|
|
|
-
|
Courses as required by the Programme co-ordinator and Advisor.
|
|
|
-
|
’An oral and/or written examination serving as a test for specialised knowledge in the discipline from which the subject for the dissertation was chosen and/or related subjects.
|
|
|
|
PHILOSOPHIAE DOCTOR:
|
|
•
|
Admission requirements:
A relevant M.Sc. or M.Pharm. degree or any qualification deemed equivalent by the Senate.
|
|
•
|
Minimum duration:
The minimum duration of the study is three years.
|
|
•
|
|
Courses:
|
|
Module |
Description |
|
FKLG991
|
Pharmacology
|
|
FCHG991
|
Pharmaceutical Chemistry
|
|
FMSG991
|
Pharmaceutics
|
|
|
•
|
Curriculum:
|
|
|
The study consists of original research leading to a thesis and/or additional examination papers as determined by the Programme co-ordinator and supervisor.
|
|
|
|
Back to top |
|
|
Sub-research programmes:
|
|
Sub-programme: Drug Delivery:
|
|
•
|
Optimal physico-chemical properties for an active pharmaceutical ingredient (API) to be effective, stable and of the highest quality to be delivered as a drug entity.
|
|
•
|
Investigation of solid-state properties of API’s and application of these principles to the design, development, manufacture and quality of drug delivery systems.
|
|
•
|
Physico-chemical determinants of dermal delivery.
|
|
•
|
Treatment of skin diseases in HIV/AIDS patients.
|
|
•
|
Enhanced dermal delivery of drugs, as well as cosmetic actives.
|
|
•
|
Enhanced delivery of drugs for the treatment of HIV/AIDS, tuberculosis and malaria using Pheroid™ technology.
|
|
•
|
Optimisation of the formulation of oral, transdermal, nasal and topical products.
|
|
|
|
Sub-programme: Drug Design and Mechanisms in Neuropsychiatry and Neuroprotection:
|
|
•
|
Drug design for membrane permeability and neuroprotection.
|
|
•
|
Metabolism and toxicity in neurodegenerative disorders.
|
|
•
|
Behavioural and neurochemical effects of acute and chronic antidepressant administration and withdrawal.
|
|
•
|
Pharmacological and neurochemical studies in an animal model of Obsessive-Compulsive Disorder (OCD).
|
|
•
|
Behavioural and neurochemical studies in an animal model of Post-Traumatic Stress Disorder (PTSD).
|
|
|
|
Back to top |
|
|
Research topics:
|
|
•
|
Sub-programme: Drug Delivery
The members of this sub-programme conduct research on drug delivery processes across biological membranes in order to deliver more patient-effective drugs and the development of novel cost-effective drug delivery systems.
|
|
|
|
|
•
|
Sub-programme: Drug Design and Mechanisms in Neuropsychiatry and Neuroprotection
The members of this sub-programme have expertise in chemical synthesis of organic compounds, chemical-physical characteristics, structure-activity relationship and drug design, metabolism, inborn metabolic errors and analytical method development.
|
|
|
|
Back to top |
|
|
Achievements and awards:
|
|
•
|
Prof DW Oliver was elected council member on the executive committee of the IUPHAR (International Union for Basic and Clinical Pharmacology);
|
|
•
|
Prof CB Brink was elected chairperson of the Teaching Committee, as well as internal auditor of IUPHAR (International Union for Basic and Clinical Pharmacology);
|
|
•
|
Proff DW Olivier and CB Brink are newly appointed NRF rated researchers as from January 2010 - we currently boast a total 10 NRF rated scientists;
|
|
•
|
We are also proud to announce that for 2010 we have awarded 8 PhD and 26 MSc’s of which 16 were with distinction.
|
|
•
|
PhD-student, Ms Marianne Güldenphennig, won the prize for best poster presentation at the recent International Anxiety Disorders Symposium.
|
|
|
|
Back to top |
|
